




The relative strengths and weaknesses of Bellerophon Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bellerophon Therapeutics Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 7.1% points. The greatest weakness of Bellerophon Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 100% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	10,382
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,584
Liabilities, Non-Current	1,659
Other Assets	2,410
Other Compr. Net Income	0
Other Expenses	-3,783
Other Liabilities	274
Other Net Income	397
Other Revenues	0
Property and Equipment	316
Research and Development	11,032
Selling, General and Administrative Expense	6,441

Output Variable	Value in 1000 USD
Assets	13,108
Liabilities	9,517
Expenses	13,690
Revenues	0
Stockholders Equity	3,591
Net Income	-13,293
Comprehensive Net Income	-13,293
BaseVar	18,356
ECR before LimitedLiability	-48%
Economic Capital Ratio	138%